Pharmacological effects and clinical application of pantogam and pantogam active

Voronina T.A.; Litvinova S.A.

doi:https://doi.org/10.17116/jnevro201711781132-139

Close metadata

Recommended articles:

Comparative study of cognitive impairment in subgroups of bipolar affective disorder types I and II, occurring with and without psychotic symptoms. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):7-11

Cognitive impairment in asthenic disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):27-32

Relationship between stroke-associated pneumonia and long-term outcomes of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):57-61

Potential of animal-derived neuropeptides in complex therapy of diabetic neuropathy in patients with type 2 diabetes mellitus. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):83-87

The main mechanisms of development of cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):13-18

Cognitive impairment in patients with multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73

Cognitive impairment after major surgical operations. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):74-80

Analysis of cognitive status in patients with different nosologies and clinical variants of very late manifesting schizophreniform psychosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):88-93

Prevalence and characteristics of risk factors for cerebrovascular disease in overweight. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):118-124

Study of the levocarnitine efficacy for the treatment of moderate cognitive impairment in patients with hypertension. Russian Journal of Preventive Medicine. 2025;(4):45-50

Abstract:

Clinical studies and experience in the use of pantogam (hopanthenic acid) and pantogam active (rac-gopantenic/D-, L-gopantenic acid) showed their efficacy and safety in patients with various pathologies. Pantogam has a unique spectrum of pharmacological effects (nootropic, anticonvulsant, mild activating) in the absence of addiction, hyperstimulation or withdrawal syndrome. Pantogam active, having also an additional anxiolytic effect, is characterized by bimodal activity, improves not only cognitive functions, but also emotional state in patients in psychiatric, neurological and cardiological practice with such diseases and conditions as anxiety/anxiety-depressive disorders, chronic brain ischemia, ischemic heart disease, chronic heart failure, arterial hypertension, epilepsy, craniocerebral trauma, schizophrenia as well as cognitive impairment in the structure of neurological and psychogenic deficiencies.

Keywords:

pantogam

pantogam active

rac-gopantenic acid

cognitive impairment

psychosomatic disorders

anxiety disorders

anxiety-depressive disorders

anxiolytic action

neurasthenia

Authors:

Voronina T.A.

NII farmakologii im. V.V. Zakusova RAMN, Moskva

SPIN RSCI: 5766-3452
Scopus AuthorID: 7103337584
ResearcherID: A-5990-2017
ORCID: 0000-0001-7065-469X

Litvinova S.A.

Zakusov State Research Institute of Pharmacology, Moscow, Russia

SPIN RSCI: 7702-5300
Scopus AuthorID: 7003645438
ResearcherID: J-4178-2018
ORCID: 0000-0001-9139-2334

Close metadata

References:

Voronina TA. Pantogam and pantogam are active. Pharmacological effects and mechanism of action. In the book: Pantogam and pantogam active. Clinical application and basic research. Ed. Kopelevich VM. M.: Triada Pharm 2009;11-30. (In Russ.).
Voronina TA. Prospects for the use of drugs with nootropic, neuroprotectiveaction. In book: Fundamental Problems of Reanimatology (Selected Lectures and Reviews). T 4. Ed. VV Moroz. M.: Izd-vo Itreanimatologii RAMS. 2005;84-113. (In Russ.).
Voronina TA Modern problems of pharmacology of nootropics: the state and prospects. Pharmacology and toxicology. 1991;54 (2):5-11. (In Russ.).
Kovler MA, Avakumov VM, Kruglikova-Lvova RP, et al. Pantogam — a new psychopharmacological tool. Chem-farm J. 1980;9:118-122. (In Russ.).
Kovalyov GI, FirstovaYuYu, Abaimov DA, Starikova NA. Qualitative and quantitative features of the interaction of pantogam and pantogam with the receptors of neurotransmitters in vitro. Journal of Neurology and Psychiatry im. S.S. Korsakova. 2012;112(3):39-43. (In Russ.).
Golosnaya GS. Possibilities of using neuroprotective drugs in the rehabilitation of children of the first year of life with perinatal hypoxic lesions of the central nervous system. Journal of Neurology and Psychiatry im. S.S. Korsakova. 2013;5(2):75-79. (In Russ.).
Ovezov AM, Lobov MA, Mashkov AE, Lugovoi AV, Panteleeva MV, Knyazev AV, Prokoshev PV, Borisova MN.The frequency of development and the possibility of correcting postoperative cognitive dysfunction in school-age children with modern variants of anesthesia. Pediatrics, application of consilium medicum. 2013;2:50-54. (In Russ.).
Aleshin IV, Zaitsev Yu.E. The effectiveness of gopanthenic acid in the complex therapy of patients with neurogenic dysfunction of the bladder. Medical advice. 2014;1:58-61. (In Russ.).
Zavadenko NN, Kozlova EV. Drug therapy for developmental dysphasia in children with nootropic drugs. Pharmath. 2013;1:34-38. (In Russ.).
Гузева В.И., Гузева В.В., Гузева О.В., Охрим И.В., Згода В.Н. Диагностика и коррекция когнитивных нарушений у детей дошкольного возраста с эпилепсией. Журнал неврологии и психиатрии им. С.С. Корсакова. 2015;115(10):51-55. [Guzeva VI, Guzeva VV, Guzeva OV, Ohrim IV, ZgodaV.N. Diagnosis and correction of cognitive impairment in preschool children with epilepsy. Journal of Neurology and Psychiatry im. S.S. Korsakova. 2015;10:51-55.
Poverennova IE, Yakunina AV, Kalinin VA, Savelieva NN. Kopelevich V.М. Efficacy and tolerability of pantogam in patients with partial epilepsy. Journal of Neurology and Psychiatry im. S.S. Korsakova. 2011;2:54-59. (iN Russ.).
Rogacheva TA, Krasnoslobodtseva LA The use of the Pantogam drug in the correction of cognitive and asthenic disorders in patients with epilepsy. Psychiatry. 2011;63(4):38-42. (In Russ.).
Катунина Е.А., Малыхина Е.А., Аванесова О.В., Макарова А.А., Абдурахманова Е.К., Гридякин В.И. Применение пантогама актив в комплексном лечении дистонических гиперкинезов. Журнал неврологии и психиатрии им. С.С. Корсакова. 2010;110:11(2):57-61. [Katunina EA, Malykhina EA, Avanesova OV, Makarova AA, Abdurakhmanova EK, Gridyakin VI. The use of pantogam in the complex treatment of dystonic hyperkinesis. Journal of Neurology and Psychiatry im. S.S. Korsakova. 2010;11(2):57-61. (In Russ.).
Chutko LS, Surushkina SYu, Nikishena IS, Yakovenko EA, Anisimova TI, Bondarchuk YuL, Aitbekov KA. Clinico-psychophysiological heterogeneity of tics in children. Pediatrics. 2013;92(6):61-67. (In Russ.).
Канаева Л.С., Вазагаева Т.И., Ястребова В.В. Перспективы применения препарата пантогам актив у больных с астеническими расстройствами. Психиатрия и психофармакотерапия. 2009;11(6):34-39. [Kanaeva L.S., Vazagaeva T.I., Yastrebova V.V. Prospects for the drug Pantogam activ in patients with asthenic disorders. Psychiatry and psycho-pharmacotherapy. 2010;11(8):34-39. (In Russ.).
Pal’tsev AI, Torgashov MN, Voronova YuS, Bayandina EV, Lunyakion SB. The role of combat stress in the formation of a chronic pain syndrome in combatants and its treatment with an active pantogram. Journal of Neurology and Psychiatry im. S.S. Korsakova. 2010;110(9):43-46. (In Russ.).
Duma SN. Evaluation of the clinical efficacy of neuroprotectors affecting the gamma-aminobutyric acid system in the treatment of cognitive disorders in patients with discirculatory encephalopathy of stages I—II. Pharmath. 2010;15:96-100. (In Russ.).
Smulevich AB, Volel BA, Ternovaya ES, Nikitina YuM. Pantogamactiv (D-, L-hopantenic acid) in the treatment of cognitive and anxiety disorders in patients with arterial hypertension. Journal of Neurology and Psychiatry im. S.S. Korsakova. 2015;12:40-49. (In Russ.).
Medvedev VE, Albantova KA. Pantogam is an active in the treatment of neurotic, stress-related, and somatoform disorders in pateriens with a c ardiac hospital. Mental disorders in general medicine. 2009;4:3-6. (In Russ.).
Medvedev BE. Neurocirculatory dystonia (cardioneurosis): an interdisciplinary approach to diagnosis and therapy. Topical issues of Neurology. 2010;3:2-6. (In Russ.).
Medvedev VE, Epiphanov AV. Thertapy for neurotic, stress-related and somatoform dsorders in patients with essential hypertension. Russia Journal of Psychiatry. 2011;1:55-56. (In Russ.).
Prevention and therapy of psycjopathological diserders in patients with cardiovascular diseases. Neurology, psyciatry and psychosomatics. 2012;3:1-6. (In Russ.).
Medvedev VE, Zverev KV, Epifanov AV, Lartseva OA, Zuykova NL, Frolova VI. Possiilities of nootropic therapy of borderline mental disorders in patients undergoing acute coronary syndrome in a cardiac hospital. Archive of internal medicine. 2013;1(9):1-9. (In Russ.).
Baranov AP, Strurynskiy AV, Oynotkinova OSh, Baranova AA, Trishina VV, Golubev YuYu, Kruzhalov AN. Possibilities of anxiety-depressive disorders treatment in patients with chronic heart failure. Cardiology. 2016;9:572-578. (In Russ.).
Sorokina IB. The main directions of neuroprospetective therapy in diseases of the nervous system. Medical advice. Psychoneurology. 2010;3-4:61-64. (In Russ.).
Putilina MV. Anxiety disorders in patients with hypertensive encephalopathy. Medical advice. 2011;3(4):107-110. (In Russ.).
Gekht AB, Kanaeva LS, Avedisova AS, Marachev MP, Zakharova KV, Dashkina GK, Kulikova EV. Possible uses of rac-gopantenic acid in the complex treatment of anxiety-depressive disorders in patients with chronic cerebral ischemia. Journal of Neurology and Psychiatry im. S.S. Korssakova. 2016;116(11):45-57. (In Russ.).
Shishkova VN, Zotova LI. The use of D-, L-gopanthenic acid in the therapy of cognitive and anxiety disorders in women with chronic cerebral ischemia and climacteric syndrome. Adverse Problems. 2015;24:1470-1475. (In Russ.).
Medvedev VE. Frolova VI, Epifanov AV. New possibilities of pharmacotherapy of mental disorders in patients with cardiovascular diseases. Journal of Neurology and Psychiatry im S.S. Korsakova. 2014;114(9):30-37. (In Russ.).
Baranov AP, Syrutynsky AV, OPinotkinova OSh, Baranova AA, Trishina VV, Golubev YuYu, Kruzhakov AN. Possibilities of therapy of anxiety-depressive disorders in patients with chronic heart failure. Russian Cardiology Journal. 2017;1:128-135. (In Russ.).
Dzhuga NP, Kozlovsky VL, Popov MYu. Effect of hapantenic acid and glycine on the efficacy o haloperidol in the treatment of patients with paranoid schizophrenia. Psychiatry and psychopharmacotherapy. 2012;14(1):20-26. (In Russ.).
Medvedev VE, Israelyan AYu, Gushanskaya EV, Frolova VI. Optimization of therapy of negative disorders in schizophrenia with the racemate of gopanthenic acid. Psychiatry and psychopharmacotherapy. 2013;15(6):30-37. (In Russ.).
Medvedev VE, Frolova VI, Ter-Israelyan AYu, Gushanskaya EV. The effectiveness of therapy with atypical antipsychotics in patients with schizophrenia in remission. Psychiary and psychopharmacotherapy. 2014;16(5):43-48. (In Russ.).
Medvedev VE, Frolova VI, Gushanskaya EV. Ter-Israelyan AYu. Augmentation of antipsychotic therapy in schizophrenia with D-, L-gopanthenic acid. Journal of Nurology and Psychiatry im. S.S. Korsakova. 2015;115(8):28-34. (In Russ.).
Tiganov AS, Panteleeva GP, Abramova LI, Bologov PV, Kananovich PS, Omel’chenko MA, Nikiforova IYu/ A differentiated approach to the improvement of methods for preventing and correcting neuroleptic secon dary extrayramidal disorders with pantogam preparation in patients with schizophrenia. Journal of Neurology and Psychiatry im. S.S. Korsakova. 2017;117(2):72-82. (In Russ.).